Thalia Therapeutics Plc (AIM:THAT)

London · Delayed Price · Currency is GBP · Price in GBX

0.5500

-0.0250 (-4.35%)

Jun 16, 2026, 12:34 PM GMT

10.00% (1Y)

Market Cap	4.79M +21.1%
Revenue (ttm)	7.07K +20.6%
Net Income	-1.10M
EPS	-0.00
Shares Out	832.28M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	17,342
Open	0.5500
Previous Close	0.5750
Day's Range	0.5500 - 0.6000
52-Week Range	0.3500 - 1.0000
Beta	0.71
Analysts	n/a
Price Target	n/a
Earnings Date	Jun 25, 2026

About Thalia Therapeutics

Thalia Therapeutics Plc, a specialist pharmaceutical company, develops nanoparticle silica delivery systems to enhance the cellular delivery and potency of cancer treatments and vaccines in the United Kingdom. It develops Nuvec, a silica nanoparticle delivery system, which has an irregular surface structure that traps and protects siRNA/RNA/DNA; and Liptide, a platform to deliver a proprietary siRNA sequence to silence a fibrotic gene. The company also engages in the development of N4 101, an orally delivered inflammation inhibitor which is in ... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 1979

Employees 4

Stock Exchange London Stock Exchange AIM

Ticker Symbol THAT

Full Company Profile

Financial Performance

In 2024, Thalia Therapeutics's revenue was 7,282, an increase of 272.86% compared to the previous year's 1,953. Losses were -1.06 million, -16.60% less than in 2023.

Financial Statements